Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Tuberculosis is the leading infectious cause of death worldwide, with 9· 6 million cases and
1· 5 million deaths reported in 2014. WHO estimates 480 000 cases of these were multidrug …

Abstract The Mycobacterium tuberculosis (Mtb) electron transport chain (ETC) has received
significant attention as a drug target, however its vulnerability may be affected by its flexibility …

Drug-resistant mycobacterial infections are a serious global health challenge, leading to
high mortality and socioeconomic burdens in develo** countries worldwide. New …

Shorter (6–9 months), fully oral regimens containing new and repurposed drugs are now the
first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long …

Abstract Drug-resistant (DR)-TB is the major challenge confronting the global TB control
programme, necessitating treatment with second-line anti-TB drugs, often with limited …

Clofazimine has been repurposed for the treatment of tuberculosis, especially for multidrug-
resistant tuberculosis (MDR-TB). To test the susceptibility to clofazimine of Mycobacterium …

Clofazimine (CZM) is an antileprosy drug that was recently repurposed for treatment of
multidrug-resistant tuberculosis. In Mycobacterium tuberculosis, CZM appears to act as a …

Objectives Although clofazimine has been traditionally used to treat leprosy, there is recent
interest in using clofazimine for the treatment of MDR-TB and drug-susceptible TB. However …

Two parallel revolutions were born in the golden era of antibiotics (~ 1940 to 1960). One
was a revolution in medicine as physicians went to war with microbes. The second was a …